This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
How Allogene (ALLO) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Allogene (ALLO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
ALLOPositive Net Change
biotechs medical
Pharma Stock Roundup: MRK to Buy Harpoon, JNJ to Acquire Ambrx Biopharma & More
by Kinjel Shah
Merck (MRK) offers to acquire Harpoon for $680 million. J&J (JNJ) is set to acquire Ambrx Biopharma for approximately $2.0 billion
JNJNegative Net Change PFENegative Net Change MRKNegative Net Change ABBVNegative Net Change
biotechs pharmaceuticals
C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn
by Zacks Equity Research
The new restructuring plan will allow C4 Therapeutics (CCCC) to extend its cash runway into 2027. The company plans to reduce its workforce by nearly 30%.
NVONegative Net Change MRKNegative Net Change SRPTPositive Net Change CCCCNegative Net Change
biotechs medical pharmaceuticals
Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results
by Zacks Equity Research
Preliminary Q4 and 2023 results from Regeneron (REGN) and Moderna (MRNA) were key highlights this week in the biotech sector.
REGNNegative Net Change GSKNegative Net Change MRNANegative Net Change EXELNegative Net Change SRPTPositive Net Change
biotechnology biotechs pharmaceuticals
Amarin (AMRN) Stock Rises on Stellar Q4 Preliminary Results
by Zacks Equity Research
Amarin (AMRN) issues encouraging preliminary results for the fourth quarter and full-year 2023. The company also plans to initiate a share repurchase program of up to $50 million. Stock gains.
AMRNNegative Net Change PBYINegative Net Change STOKPositive Net Change
biotechs
Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC
by Zacks Equity Research
Mirati's (MRTX) Krazati gets the European Commission's conditional marketing approval for treating adult patients with KRASG12C-mutated advanced non-small cell lung cancer.
BMYNegative Net Change PBYINegative Net Change MRTXPositive Net Change
biotechs
Xeris (XERS) Up on Licensing Deal With Amgen to Develop Tepezza
by Zacks Equity Research
Xeris (XERS) gains 16% after signing a licensing deal with Amgen, which allows the latter to utilize the XeriJect technology to develop a subcutaneous formulation of teprotumumab in Thyroid Eye Disease.
AMGNNegative Net Change PBYINegative Net Change ADMAPositive Net Change XERSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Here's Why You Should Invest in Ocuphire Pharma (OCUP) Now
by Zacks Equity Research
Here, we discuss some reasons why buying Ocuphire Pharma (OCUP) stock now may turn out to be a prudent move.
REGNNegative Net Change PBYINegative Net Change VTRSNegative Net Change
biotechs
Why Sarepta's (SRPT) Stock Price Moved Up 17% on Tuesday
by Zacks Equity Research
Sarepta (SRPT) surges after its CEO made positive comments on the label expansion filing for the company's DMD gene therapy. The company expects a potential approval in August.
RHHBYNegative Net Change SRPTPositive Net Change CTMXNegative Net Change SLDBNo Net Change
biotechs gene-therapy medical pharmaceuticals
Prothena's (PRTA) Update on Pipeline Progress Disappoints
by Zacks Equity Research
Prothena (PRTA) provides updates on PRX012, PRX123, birtamimab and other programs. The delay in phase III data on birtamimab disappoints investors.
BIIBNegative Net Change RHHBYNegative Net Change BMYNegative Net Change PRTANegative Net Change
biotechnology biotechs
SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
by Zacks Equity Research
The FDA bestows a Fast Track Designation to SELLAS' (SLS) pipeline candidate, SLS009, for the treatment of relapsed/refractory acute myeloid leukemia. Stock gains.
SRPTPositive Net Change PBYINegative Net Change SLSNo Net Change
biotechs
Atea Pharma (AVIR) Gains on Upbeat Initial Data From HCV Study
by Zacks Equity Research
Atea Pharma (AVIR) gains 11% after reporting positive initial results from the first 52 patients in the lead-in cohort of the mid-stage study evaluating its bemnifosbuvir/RZR combo to treat HCV.
PBYINegative Net Change ADMAPositive Net Change ACADNegative Net Change AVIRNegative Net Change
biotechnology biotechs medical pharmaceuticals
MeiraGTx (MGTX): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
MeiraGTx (MGTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
MGTXPositive Net Change
biotechs medical
GSK to Buy Private Biotech, Strengthen Respiratory Pipeline
by Zacks Equity Research
GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.
REGNNegative Net Change GSKNegative Net Change SRPTPositive Net Change PBYINegative Net Change
biotechs
Cytokinetics (CYTK) Rises on Reports of Buyout by Novartis
by Zacks Equity Research
Cytokinetics (CYTK) shares gain on reports of acquisition by pharma giant Novartis.
NVSNegative Net Change BMYNegative Net Change CYTKNegative Net Change ABBVNegative Net Change
biotechnology biotechs pharmaceuticals
Moderna (MRNA) Issues 2023 Preliminary Results, Stock Up 4%
by Zacks Equity Research
Moderna (MRNA) reports unaudited product sales of around $6.7 billion for 2023, meeting its previously issued guidance. Share price rises following the announcement.
NVONegative Net Change MRKNegative Net Change MRNANegative Net Change CTMXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Ambrx (AMAM) Skyrockets 102% on $2B Buyout Offer From J&J
by Zacks Equity Research
J&J (JNJ) is set to acquire Ambrx Biopharma (AMAM) in an all-cash transaction for $2.0 billion. The transaction will likely close in first-half 2024.
JNJNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechs medical pharmaceuticals
Novo Nordisk's (NVO) Phase III Diabetes Study Meets Primary Goal
by Zacks Equity Research
Novo Nordisk (NVO) reports positive top-line data from one of its late-stage studies under the COMBINE program evaluating once-weekly IcoSema in type II diabetes patients.
NVONegative Net Change PBYINegative Net Change ADMAPositive Net Change ACADNegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron (REGN) Down as Q4 Eylea Preliminary Sales Disappoint
by Zacks Equity Research
Regeneron (REGN) shares decline after it announces preliminary Q4 sales for the ophthalmology drug Eylea.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs pharmaceuticals
Biotech ETFs Stage Solid Comeback at the Start of 2024
by Sweta Killa
The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.
BMYNegative Net Change JNJNegative Net Change MRKNegative Net Change IBBNegative Net Change XBINegative Net Change BBHNegative Net Change BBPNegative Net Change IBBQNegative Net Change
biotechs etfs
Sarepta (SRPT) Rises on Solid Q4 and 2023 Preliminary Results
by Zacks Equity Research
Sarepta (SRPT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise.
RHHBYNegative Net Change SRPTPositive Net Change PBYINegative Net Change ANABNegative Net Change
biotechs
Apellis (APLS) Up on Strong Q4 Preliminary Syfovre U.S. Revenues
by Zacks Equity Research
Apellis (APLS) reports strong preliminary net product revenues in the United States for the fourth quarter of 2023, driven by robust Syfovre sales. The stock gains 15%.
PBYINegative Net Change ADMAPositive Net Change ACADNegative Net Change APLSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Anavex (AVXL): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Anavex (AVXL) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
AVXLNegative Net Change
biotechs medical
Merck (MRK) to Strengthen Cancer Pipeline With Harpoon Buyout
by Zacks Equity Research
Merck's (MRK) Harpoon buyout is expected to strengthen its oncology pipeline by adding the latter's lead pipeline candidate, HPN328, a T cell engager being studied for SCLC and neuroendocrine tumors.
JNJNegative Net Change MRKNegative Net Change HARPNegative Net Change
biotechs pharmaceuticals
Alnylam (ALNY) Posts Preliminary Q4 & Full-Year '23 Revenues
by Zacks Equity Research
Alnylam (ALNY) reports preliminary full-year and fourth-quarter 2023 net product revenues.
ALNYNegative Net Change PBYINegative Net Change ADMAPositive Net Change ACADNegative Net Change
biotechnology biotechs medical pharmaceuticals